Sign Up Today and Learn More About Electra Therapeutics Stock
Invest in or calculate the value of your shares in Electra Therapeutics or other pre-IPO companies through EquityZen's platform.
Electra Therapeutics Stock
Electra Therapeutics is a clinical-stage biotechnology company developing antibody therapies for immunological diseases and cancer.
About Electra Therapeutics Stock
Founded
2018
Headquarters
San Francisco, CA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Electra Therapeutics Press Mentions
Stay in the know about the latest news on Electra Therapeutics
Swiss HBM Healthcare nine-month profit hits CHF 286 mln as NAV jumps 18%
investing • Jan 23, 2026
Macrophage Activation Syndrome Market in the 6MM to Witness Upsurge in Growth at a CAGR of 24.7% During the Forecast Period (2025-2034) | DelveInsight
prnewswire • Jan 16, 2026
Macrophage Activation Syndrome Market in the 6MM to Witness Upsurge in Growth at a CAGR of 24.7% During the Forecast Period (2025-2034) | DelveInsight
prnewswire • Jan 16, 2026
Electra Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
globenewswire • Jan 05, 2026
Electra Therapeutics Presents SURPASS Pivotal ELA026 Study Design and Highlights the Critical Unmet Need in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) at the ASH 2025 Annual Meeting
globenewswire • Dec 02, 2025
Electra Therapeutics Management
Leadership team at Electra Therapeutics
Board Observer
Vijay Lathi
Board Observer
Amrit Nagpal
Join now and verify your accreditation status to gain access to:
- Electra Therapeutics Current Valuation
- Electra Therapeutics Stock Price
- Electra Therapeutics Management
- Available deals in Electra Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Electra Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Electra Therapeutics Revenue and Financials
- Electra Therapeutics Highlights
- Electra Therapeutics Business Model
- Electra Therapeutics Risk Factors
- Electra Therapeutics Research Report from SACRA Research
Trading Electra Therapeutics Stock
How to invest in Electra Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Electra Therapeutics through EquityZen funds. These investments are made available by existing Electra Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Electra Therapeutics stock?
Shareholders can sell their Electra Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 430K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 52K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."